Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Perioperative Treatment in Resectable Gastric Cancer With Spartalizumab (PDR001) in Combination With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT): A Phase II Study (GASPAR)

NCT04736485 is registered in ClinicalTrials.gov with Centre Francois Baclesse as lead sponsor.

NCT NCT04736485
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04736485 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Perioperative Treatment in Resectable Gastric Cancer With Spartalizumab (PDR001) in Combination With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT): A Phase II Study (GASPAR)
Lead sponsor
Centre Francois Baclesse
Phase
Phase 2
Overall status
Completed
Start date
June 28, 2021
Completion date
November 27, 2025
Enrollment
67 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer by ajcc v8 stage, resectable carcinoma